Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC)

MLA

Pilar Lardelli, et al. “Activity of Lurbinectedin as Single Agent and in Combination in Patients with Advanced Small Cell Lung Cancer (SCLC).” Lung Cancer, vol. 115, Jan. 2018, p. S72. EBSCOhost, https://doi.org/10.1016/s0169-5002(18)30192-2.

APA

Pilar Lardelli, V. Moreno, Arturo Soto-Matos, Emiliano Calvo, M.P. Lopez Criado, J.A. Lopez-Vilarino de Ramos, Martin Forster, X.E. Luepke-Estefan, M.E. Olmedo García, & Carmen Kahatt. (2018). Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC). Lung Cancer, 115, S72. https://doi.org/10.1016/s0169-5002(18)30192-2

Chicago

Pilar Lardelli, V. Moreno, Arturo Soto-Matos, Emiliano Calvo, M.P. Lopez Criado, J.A. Lopez-Vilarino de Ramos, Martin Forster, X.E. Luepke-Estefan, M.E. Olmedo García, and Carmen Kahatt. 2018. “Activity of Lurbinectedin as Single Agent and in Combination in Patients with Advanced Small Cell Lung Cancer (SCLC).” Lung Cancer 115 (January): S72. doi:10.1016/s0169-5002(18)30192-2.